Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Cell Cycle (Georgetown, Tex.)|April 4, 2006
Halting neuroblastoma metastasis by controlling integrin-mediated deathTal Teitz, Dwayne G Stupack, Jill M Lahti
Cancer Research|June 17, 2006
Does integrin-mediated cell death confer tissue tropism in metastasis?Jill M Lahti, Tal Teitz, Dwayne G Stupack
Methods in Molecular Biology (Clifton, N.J.)|June 5, 2016
Development of Cell-Based High-Throughput Chemical Screens for Protection Against Cisplatin-Induced OtotoxicityTal Teitz, Asli N Goktug, Taosheng Chen, et al.
Neoplasia (New York, N.Y.)|November 4, 2025
Oral AZD5438 is a clinically translatable otoprotectant against cisplatin-induced hearing lossYunlong Huang, Xintian Zhang, Enrick Vesanes, et al.
Pharmaceuticals (Basel, Switzerland)|June 27, 2024
Trametinib, a MEK1/2 Inhibitor, Protects Mice from Cisplatin- and Noise-Induced Hearing LossRichard D Lutze, Matthew A Ingersoll, Regina G Kelmann, et al.
Biorxiv : the Preprint Server for Biology|June 3, 2024
FDA-Approved MEK1/2 Inhibitor, Trametinib, Protects Mice from Cisplatin and Noise-Induced Hearing LossRichard D Lutze, Matthew A Ingersoll, Regina G Kelmann, et al.
International Journal of Molecular Sciences|June 27, 2024
ERK1/2 Inhibition via the Oral Administration of Tizaterkib Alleviates Noise-Induced Hearing Loss While Tempering down the Immune ResponseRichard D Lutze, Matthew A Ingersoll, Alena Thotam, et al.
Biorxiv : the Preprint Server for Biology|October 31, 2023
ERK1/2 Inhibition Alleviates Noise-Induced Hearing Loss While Tempering Down the Immune ResponseRichard D Lutze, Matthew A Ingersoll, Alena Thotam, et al.
Journal of the American Society of Nephrology : JASN|November 14, 2023
Repurposing AZD5438 and Dabrafenib for Cisplatin-Induced AKIChithra K Pushpan, Daniel F Kresock, Matthew A Ingersoll, et al.
Pageof 3